Options for radionuclide therapy: From fixed activity to patient-specific treatment planning

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 1, 2002, Pages 71-82

  Thomas, Stephen R ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM PHOSPHATE P 32; DYSPROSIUM IRON HYDROXIDE DY 165; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY I 131; ETIDRONIC ACID RE 186; IODINE 125; IODINE 131; LEXIDRONAM SAMARIUM SM 153; MACROSALB I 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425 I 125; PENTETREOTIDE IN 111; PHOSPHORUS 32; RADIOISOTOPE; SILICATE; SILICATE COLLOID Y 90; SODIUM DIHYDROGEN PHOSPHATE; SODIUM DIHYDROGEN PHOSPHATE P 32; SODIUM IODIDE I 131; STRONTIUM 89; STRONTIUM CHLORIDE; STRONTIUM CHLORIDE SR 89; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTHRITIS; CALCULATION; CLINICAL PROTOCOL; CONFERENCE PAPER; DOSE CALCULATION; FOLLOW UP; GLIOBLASTOMA; GLIOMA; GRAVES DISEASE; HUMAN; MONTE CARLO METHOD; NEUROBLASTOMA; OVARY CANCER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; THREE DIMENSIONAL IMAGING; THYROID CANCER; TREATMENT PLANNING;

EID: 0036189414     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/10849780252824091     Document Type: Conference Paper

References (50)

1. Use of therapeutic radionuclides in medicine
2. Radionuclide therapy revisited
3. Radionuclide therapy
4. The treatment of polycythemia vera
5. Estimation of dosage for intravenously administered P-32
6. Radioactive isotopes in haematologic therapy
7. Radiation exposure from radioisotopes in pediatrics
8. The absorbed dose to bone marrow in the treatment of polycythemia by P-32
9. P-32 Therapy in polycythemia vera. Chapter 11
10. Polycythemia vera and leukemia - The role of radiation treatment. A study of 1222 patients
11. Polycythemia vera: A retrospective and reprise
12. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
13. Radioactive iodine as an indicator in thyroid physiology: Use of radioactive iodine in differential diagnosis of 2 types of Graves' disease
14. The invention of radioiodine treatment of hyperthyroidism: Part 1
15. The invention of radioiodine treatment of hyperthyroidism: Part 2
16. The impact of technology on clinical practice in Graves' disease
17. Retreatment of Graves' disease with radioiodine 131I
18. Radionuclide therapy of the thyroid
19. Blood radiation dose after 131-I therapy of thyrotoxicosis. Calculations with reference to leukemia
20. Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the cooperative thyrotoxicosis follow-up study
21. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism. A report of the cooperative thyrotoxicosis follow-up study
22. Cancer mortality following treatment for adult hyperthyroidism
23. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer
24. Treatment of thyroid cancer with radioactive iodine. Chapter 25
25. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine
26. Whole body scanning and 1-131 therapy in the management of thyroid carcinoma
27. The use of radioiodine in the management of thyroid cancer
28. The ablation of normal thyroid tissue with iodine-131
29. The role of I-131 in the treatment of thyroid cancer
30. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer
31. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates
32. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry
33. 131I on postsurgical thyroid remnants
34. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer
35. Relationship between effective radiation dose and outcome of radioiodine therapy for thyroid cancer
36. Systemic radiation therapy with unsealed radionuclides
37. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic prospective
38. Impact of therapy for differentiated carcinoma of the thyroid: An analysis of 706 cases
39. Natural history, treatment, and course of papillary thyroid carcinoma
40. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
41. Clinical radioimmunotherapy
42. Introduction
43. A Monte Carlo approach to patient-specific dosimetry
44. A Monte Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system
45. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry
46. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing